Immunospecific Therapy for Type I Diabetes Mellitus

Publisher Website
Google Scholar
Abstract
To the Editor: Evidence implicating immunologic mechanisms in the pathogenesis of Type I diabetes mellitus1 , 2 has led to clinical trials of immunosuppressive therapy.3 , 4 Recently, cyclosporine has been reported5 to decrease insulin requirements when its use is initiated after Type I diabetes is diagnosed. However, the apparent requirement for long-term therapy and concerns about toxicity with this agent point to a need for more immunospecific therapy.We administered the antiblast monoclonal antibody CBL1 to a group of children with newly diagnosed diabetes to investigate the possibility that destruction of a subpopulation of activated T lymphocytes with this antibody would limit . . .